Direct-acting Antiviral Drug Market to Grow with a CAGR of 12.86% through 2030
Increasing
government initiatives for hepatitis C elimination and expanding healthcare
access in emerging economies, is expected to drive the Global Direct-acting
Antiviral Drug Market growth in the forecast period, 2026-2030
According to TechSci Research report, “Direct-acting Antiviral Drug Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Direct-acting Antiviral Drug Market stood at USD 11.41 Billion in 2024 and is expected to reach USD 23.61 Billion by 2030 with a CAGR of 12.86% during the forecast period. The global direct-acting antiviral (DAA) drug market is experiencing significant expansion due to the rising demand for targeted antiviral therapies. These drugs directly inhibit viral replication, offering an efficient alternative to traditional treatments. Increasing advancements in molecular biology and drug formulation technologies have resulted in highly potent DAAs with fewer side effects. The growing burden of chronic viral infections, particularly hepatitis C, is pushing healthcare systems to integrate these therapies into standard treatment protocols. The adoption of combination regimens has improved therapeutic outcomes, leading to higher cure rates. Efforts to simplify treatment guidelines and enhance drug accessibility are further supporting market expansion.
The rising prevalence of viral infections and the increasing need for effective treatment options are key factors driving market growth. Enhanced screening programs are enabling earlier detection, leading to timely interventions with DAAs. Pharmaceutical innovations in antiviral drug design, including protease and polymerase inhibitors, are improving drug performance and reducing treatment duration. The shift toward single-dose regimens is enhancing patient compliance and reducing healthcare costs. Partnerships between biotech firms and pharmaceutical companies are accelerating the introduction of new antiviral formulations. Regulatory support for expedited approvals of breakthrough therapies is fostering innovation in the sector. Growing investments in antiviral research are creating a strong pipeline of next-generation DAAs, ensuring continuous advancements in treatment approaches.
Expanding access to antiviral therapies in underserved regions presents a major opportunity for market growth. The integration of artificial intelligence in drug discovery is accelerating the development of more precise and targeted antiviral compounds. Advances in nanotechnology-based drug delivery systems are enhancing the effectiveness of DAAs by improving bioavailability and reducing side effects. The emergence of pan-genotypic antiviral treatments is broadening the patient base, allowing for more inclusive treatment options. Collaborations between pharmaceutical firms and public health organizations are expected to strengthen efforts toward global viral infection eradication. With continuous innovations and strategic partnerships, the DAA drug market is poised for sustained expansion in the coming years.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global Direct-acting Antiviral Drug Market”
The Global Direct-acting
Antiviral Drug Market is segmented into type, indication, route, distribution
channel, regional distribution, and company.
Based on the Type, NS3/4A Protease emerged as the fastest growing segment in the Global Direct-acting Antiviral Drug Market during the forecast period. This is due to several
compelling factors. Firstly, its efficacy in combating hepatitis C, a major
global health concern, has been well-documented and widely acknowledged. This
track record of success has established NS3/4A Protease as a trusted and
reliable treatment option among healthcare professionals and patients alike.
Moreover, ongoing research and development efforts are continuously enhancing
its capabilities, ensuring its relevance in the evolving landscape of antiviral
drugs. Additionally, the market's increasing demand for highly effective and
targeted treatments, coupled with the growing awareness of the importance of
early intervention in viral infections, will further bolster NS3/4A Protease's
market presence. In conclusion, the combination of its proven effectiveness,
ongoing innovation, and market demand positions NS3/4A Protease as the
frontrunner in the Global Direct-acting Antiviral Drug Market for the
foreseeable future.
Based on the Region, Asia-Pacific emerged as the fastest growing region in the Global Direct-acting Antiviral Drug Market during the forecast period. The Asia-Pacific region is benefiting from robust research and development activities in the field of antiviral drug development. Many leading pharmaceutical companies and research institutions in countries like South Korea and Australia are actively engaged in developing next-generation DAAs with improved efficacy and safety profiles. The region’s growing biotech industry, supported by strong government funding and regulatory advancements, is accelerating the introduction of innovative antiviral therapies. In addition, the rise of medical tourism in countries such as Thailand, Singapore, and India has increased demand for advanced antiviral treatments, further fueling market expansion. The presence of a large patient pool, coupled with an increasing preference for combination DAA therapies, is driving investments from global pharmaceutical firms looking to establish a strong foothold in the region. Furthermore, the emergence of telemedicine and digital healthcare solutions has improved patient engagement and adherence to antiviral treatment regimens, strengthening market growth. With continued advancements in healthcare infrastructure, regulatory policies, and antiviral research, Asia-Pacific is expected to maintain its position as the fastest-growing region in the Global Direct-acting Antiviral Drug Market.
Major companies
operating in Global Direct-acting Antiviral Drug Market are:
- Natco Pharma Ltd
- Vertex Pharmaceuticals Inc
- Dr Reddy's Laboratories Ltd
- Johnson & Johnson
- Merck & Co Inc
- Gilead Sciences Inc
- AbbVie Inc
- Bristol-Myers Squibb Co
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global
Direct-acting Antiviral Drug Market is expanding due to the increasing
development of fixed-dose combination therapies, which simplify treatment
regimens and enhance patient adherence. These combination drugs integrate
multiple direct-acting antivirals (DAAs) into a single formulation, reducing
pill burden and minimizing the risk of drug resistance. With growing demand for
convenient and effective antiviral treatments, pharmaceutical companies are
focusing on developing novel combination therapies that improve cure rates and
treatment efficiency. Regulatory agencies are also supporting these
advancements by expediting approvals for innovative antiviral combinations,
further accelerating market growth.,” said Mr. Karan Chechi, Research Director
of TechSci Research, a research-based management consulting firm.
“Direct-acting Antiviral
Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA
polymerase), By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis),
By Route (Intravenous, Oral, Subcutaneous, Topical), By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and
Competition, 2020-2030F”, has evaluated the future growth potential of Global
Direct-acting Antiviral Drug Market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in
Global Direct-acting Antiviral Drug Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com